T Foltynie

Summary

Affiliation: University of Cambridge
Country: UK

Publications

  1. ncbi Vascular parkinsonism: a review of the precision and frequency of the diagnosis
    Thomas Foltynie
    Cambridge Centre for Brain Repair, University of Cambridge, Cambridge, UK
    Neuroepidemiology 21:1-7. 2002
  2. ncbi Cognitive deficits and psychosis in Parkinson's disease: a review of pathophysiology and therapeutic options
    Caroline H Williams-Gray
    Cambridge Centre for Brain Repair, University of Cambridge, Cambridge, UK
    CNS Drugs 20:477-505. 2006
  3. ncbi The frequency and validity of self-reported diagnosis of Parkinson's Disease in the UK elderly: MRC CFAS cohort
    Thomas Foltynie
    Cambridge Centre for Brain Repair, University of Cambridge, Forvie Site, Robinson Way, Cambridge, CB2 2PY, UK
    BMC Neurol 6:29. 2006
  4. ncbi The BDNF Val66Met polymorphism has a gender specific influence on planning ability in Parkinson's disease
    Thomas Foltynie
    Cambridge Centre for Brain Repair, University of Cambridge, Forvie Site, Robinson Way, Cambridge CB2 2PY, UK
    J Neurol 252:833-8. 2005
  5. ncbi A genome wide linkage disequilibrium screen in Parkinson's disease
    Thomas Foltynie
    Dept of Neurology, University of Cambridge, Cambridge, CB2 2PY, UK
    J Neurol 252:597-602. 2005
  6. ncbi Planning ability in Parkinson's disease is influenced by the COMT val158met polymorphism
    Thomas Foltynie
    Cambridge Centre for Brain Repair, University of Cambridge, United Kingdom
    Mov Disord 19:885-91. 2004
  7. ncbi The cognitive ability of an incident cohort of Parkinson's patients in the UK. The CamPaIGN study
    Thomas Foltynie
    Cambridge Centre for Brain Repair, University of Cambridge, Forvie Site, Robinson Way, Cambridge CB2 2PY, UK
    Brain 127:550-60. 2004
  8. ncbi The genetic basis of Parkinson's disease
    T Foltynie
    Cambridge Centre for Brain Repair, University of Cambridge, Cambridge, UK
    J Neurol Neurosurg Psychiatry 73:363-70. 2002
  9. ncbi Prevalence of the LRRK2 G2019S mutation in a UK community based idiopathic Parkinson's disease cohort
    C H Williams-Gray
    Cambridge Centre for Brain Repair, Department of Clinical Neurosciences, University of Cambridge, Forvie Site, Robinson Way, Cambridge CB2 2PY, UK
    J Neurol Neurosurg Psychiatry 77:665-7. 2006
  10. ncbi BDNF val66met influences time to onset of levodopa induced dyskinesia in Parkinson's disease
    T Foltynie
    Cambridge Centre for Brain Repair, Cambridge, UK
    J Neurol Neurosurg Psychiatry 80:141-4. 2009

Collaborators

Detail Information

Publications22

  1. ncbi Vascular parkinsonism: a review of the precision and frequency of the diagnosis
    Thomas Foltynie
    Cambridge Centre for Brain Repair, University of Cambridge, Cambridge, UK
    Neuroepidemiology 21:1-7. 2002
    ....
  2. ncbi Cognitive deficits and psychosis in Parkinson's disease: a review of pathophysiology and therapeutic options
    Caroline H Williams-Gray
    Cambridge Centre for Brain Repair, University of Cambridge, Cambridge, UK
    CNS Drugs 20:477-505. 2006
    ..Modafinil improves alertness in Parkinson's disease and warrants further investigation to establish its effects on cognitive performance...
  3. ncbi The frequency and validity of self-reported diagnosis of Parkinson's Disease in the UK elderly: MRC CFAS cohort
    Thomas Foltynie
    Cambridge Centre for Brain Repair, University of Cambridge, Forvie Site, Robinson Way, Cambridge, CB2 2PY, UK
    BMC Neurol 6:29. 2006
    ..Estimates of the incidence and prevalence of chronic diseases can be made using established cohort studies but these estimates may have lower reliability if based purely on self-reported diagnosis...
  4. ncbi The BDNF Val66Met polymorphism has a gender specific influence on planning ability in Parkinson's disease
    Thomas Foltynie
    Cambridge Centre for Brain Repair, University of Cambridge, Forvie Site, Robinson Way, Cambridge CB2 2PY, UK
    J Neurol 252:833-8. 2005
    ..We speculate that BDNF may interact with dopaminergic transmission and dopamine receptor stimulation in the frontostriatal circuitry, with subsequent consequences on cognition in Parkinson's disease...
  5. ncbi A genome wide linkage disequilibrium screen in Parkinson's disease
    Thomas Foltynie
    Dept of Neurology, University of Cambridge, Cambridge, CB2 2PY, UK
    J Neurol 252:597-602. 2005
    ..Subgroup analysis of the most promising marker shows some evidence that microsatellite marker D1S2886 is associated with familial forms of the disease...
  6. ncbi Planning ability in Parkinson's disease is influenced by the COMT val158met polymorphism
    Thomas Foltynie
    Cambridge Centre for Brain Repair, University of Cambridge, United Kingdom
    Mov Disord 19:885-91. 2004
    ..We suggest that polymorphisms of common genes, which regulate central nervous system dopaminergic transmission, can influence some of the phenotypic manifestations of PD...
  7. ncbi The cognitive ability of an incident cohort of Parkinson's patients in the UK. The CamPaIGN study
    Thomas Foltynie
    Cambridge Centre for Brain Repair, University of Cambridge, Forvie Site, Robinson Way, Cambridge CB2 2PY, UK
    Brain 127:550-60. 2004
    ....
  8. ncbi The genetic basis of Parkinson's disease
    T Foltynie
    Cambridge Centre for Brain Repair, University of Cambridge, Cambridge, UK
    J Neurol Neurosurg Psychiatry 73:363-70. 2002
    ..The identification of such susceptibility genes will eventually enable us to more accurately classify this complex disease...
  9. ncbi Prevalence of the LRRK2 G2019S mutation in a UK community based idiopathic Parkinson's disease cohort
    C H Williams-Gray
    Cambridge Centre for Brain Repair, Department of Clinical Neurosciences, University of Cambridge, Forvie Site, Robinson Way, Cambridge CB2 2PY, UK
    J Neurol Neurosurg Psychiatry 77:665-7. 2006
    ..The true prevalence of the mutation in idiopathic disease, its penetrance, and the phenotypic heterogeneity of associated cases have important implications for genetic screening in the clinical field...
  10. ncbi BDNF val66met influences time to onset of levodopa induced dyskinesia in Parkinson's disease
    T Foltynie
    Cambridge Centre for Brain Repair, Cambridge, UK
    J Neurol Neurosurg Psychiatry 80:141-4. 2009
    ..There is accumulating evidence that LID develop due to abnormal synaptic plasticity, which is in turn influenced by the release of brain derived neurotrophic factor (BDNF)...
  11. ncbi Evolution of cognitive dysfunction in an incident Parkinson's disease cohort
    C H Williams-Gray
    Cambridge Centre for Brain Repair, Department of Clinical Neurosciences, University of Cambridge, Forvie Site, Robinson Way, Cambridge, CB2 2PY, UK
    Brain 130:1787-98. 2007
    ..Furthermore, given that these predictors of dementia are readily measurable within just a few minutes in a clinical setting, our work may ultimately have practical implications in terms of guiding prognosis in individual patients...
  12. ncbi Saccadic latency distributions in Parkinson's disease and the effects of L-dopa
    A W Michell
    Cambridge Centre for Brain Repair, Forvie Site, Robinson Way, CB2 2PY, Cambridge, UK
    Exp Brain Res 174:7-18. 2006
    ....
  13. ncbi Heterogeneity of Parkinson's disease in the early clinical stages using a data driven approach
    S J G Lewis
    Cambridge Centre for Brain Repair, Forvie Site, Addenbrooke s Hospital, Cambridge, CB2 2PY, UK
    J Neurol Neurosurg Psychiatry 76:343-8. 2005
    ..To investigate the heterogeneity of idiopathic Parkinson's disease (PD) in a data driven manner among a cohort of patients in the early clinical stages of the disease meeting established diagnostic criteria...
  14. ncbi Biomarkers and Parkinson's disease
    A W Michell
    Cambridge Centre for Brain Repair, Forvie Site, Robinson Way, CB2 2PY, UK
    Brain 127:1693-705. 2004
    ..In this review we discuss the current potential biomarkers for Parkinson's disease, highlight the problems with their use, and conclude with a discussion of future alternatives...
  15. ncbi A genome-wide screen for association in Hungarian multiple sclerosis
    Cecilia Rajda
    Department of Neurology, University of Szeged, Semmelweis u. 6, H-6725 Szeged, Hungary
    J Neuroimmunol 143:84-7. 2003
    ..These markers were typed in DNA pools that consisted of 88 MS patients (cases), and 128 unrelated controls. Based on a stringent selection criterion, we obtained 33 markers suggesting association with the disease...
  16. ncbi Tau and alpha-synuclein in susceptibility to, and dementia in, Parkinson's disease
    An Goris
    Department of Clinical Neurosciences Neurology Unit, University of Cambridge, Cambridge, United Kingdom
    Ann Neurol 62:145-53. 2007
    ..We investigated the genetic basis of susceptibility to and cognitive heterogeneity of this disease...
  17. ncbi The heterogeneity of idiopathic Parkinson's disease
    Thomas Foltynie
    Cambridge Centre for Brain Repair, University of Cambridge, UK
    J Neurol 249:138-45. 2002
    ....
  18. ncbi A whole genome association study in multiple sclerosis patients from north Portugal
    Berta Martins Silva
    Pathology and Molecular Immunology Department, Instituto Ciências Biomédicas Abel Salazar, University of Porto, Porto, Portugal
    J Neuroimmunol 143:116-9. 2003
    ..When compared to a physical map three regions were found with two of these markers less than 1.5 Mb apart: chromosomes 6p21.3 (the MHC region), 6q14.1 and 7q34...
  19. ncbi UCHL-1 is not a Parkinson's disease susceptibility gene
    Daniel G Healy
    Department of Molecular Neuroscience, Institute of Neurology, University College London, London, United Kingdom
    Ann Neurol 59:627-33. 2006
    ..The strongest evidence comes from a meta-analysis of small studies that reported the S18Y polymorphism as protective against PD, after pooling studies of white and Asian subjects. Here, we present data that challenge this association...
  20. ncbi Mitochondrial DNA haplogroup cluster UKJT reduces the risk of PD
    Angela Pyle
    Mitochondrial Research Group, The University of Newcastle upon Tyne, Newcastle upon Tyne, United Kingdom
    Ann Neurol 57:564-7. 2005
    ....
  21. ncbi The future challenges in Parkinson's disease
    Roger A Barker
    Cambridge Centre for Brain Repair and Department of Neurology, Forvie Site, Robinson Way, Cambridge, CB2 2PY, UK
    J Neurol 251:361-5. 2004
  22. ncbi No alterations in alpha-synuclein gene dosage observed in sporadic Parkinson's disease
    Caroline H Williams-Gray
    Mov Disord 21:731-2. 2006